We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

Amgen Inc.
People also watch : BIIB GILD CELG MRK BMY
172.03 0.75 (0.44%)

After hours: 172.400.37 (0.22%) as of 7:59 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close 171.28
Open 171.57
Bid 172.40 x 400
Ask 172.74 x 100
52wk Range 130.09 - 177.52
Day's Range 170.53 - 172.26
Volume 3,121,594
Avg Vol (3m) 2,851,373
As of 4:00 PM EDT. Market closed.
  • Market Realist 17 hours ago

    Amgen’s Bone Health Drug Saw Strong Revenue Growth in 2Q16

    Amgen’s (AMGN) bone health drugs Prolia and Xgeva earn a combined $3 billion in revenue annually.

  • Market Realist 17 hours ago

    Growth Products Drove Amgen’s Revenue Performance in 2Q16

    Amgen declared its 2Q16 earnings on July 27, 2016. The company reported diluted earnings per share of about $2.52 in 2Q16, a year-over-year rise of ~11.4%.

  • Zacks 17 hours ago

    Top 7 Research Reports for July 29, 2016

    Top 7 Research Reports for July 29, 2016

  • Market Realist 17 hours ago

    Amgen Continued to Manage Life Cycles of Its Mature Brands in Q2

    While focusing on its growth products, Amgen has also been actively involved in managing the life cycles of its mature brands Neupogen and Neulasta.

  • Forbes 18 hours ago

    Amgen's Drug Pipeline Fortifying A Biotech Pioneer

    Despite Amgen’s blockbuster patents nearing expiration, it has the potential to riposte with a competitive pipeline and drug profile.

  • Barrons.com 19 hours ago

    Biotech Stocks: The End of Political Risk?

    RBC's Michael Yee and team contend that biotech stocks like Amgen (AMGN), Biogen (BIIB), Celgene (CELG), Gilead Sciences (GILD), and Alexion Pharmaceuticals (ALXN) are looking past the political risks: The SPDR S&P Biotech ETF (XBI) biotech index is up +13% in a month vs S&P500 +5% and we think political rhetoric and fear about drug pricing legislation which has been one of the primary overhangs on biotech stocks could be starting to move behind us as we go into H2:16. Indeed, given the large correction in the past year and rotation out of biotech, we think the market is starting to get more comfortable with the political environment and this could be an important shift and one of the key factors in driving stocks higher and removing the overhang.

  • TheStreet.com yesterday

    Here's When You Should Buy Amgen

    A healthy pullback in Amgen would create a low-risk buying opportunity.

  • Barrons.com yesterday

    [$$] Amgen EPS Set to Rise Through 2018

    Amgen (AMGN:Nasdaq) By Credit Suisse ($170.68, July 28, 2016) We raise our 2016, 2017 and 2018 earnings-per-share estimates for Amgen to $11.38, $12.64 and $13.39, respectively, from $11.14, $12.10 and $12.91. Neulasta biosimilar competition is likely delayed pushing it later into 2017.

  • Forbes 2 days ago

    What Are Analysts Saying About Q2 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead

    Second-quarter earnings season has been going for more than a week, and we’ve had a chance to hear from all four of the biggest companies in biotech as measured by sales, market valuation and clout. Here’s what they had to say in their business updates, along with some commentary from analysts

  • Amgen’s Drug Pipeline Fortifying A Biotech Pioneer
    Yahoo Finance Contributors 18 hours ago

    Amgen’s Drug Pipeline Fortifying A Biotech Pioneer